An update to the British Society for Rheumatology (BSR) Guideline for the management of gout has been published.

Gout is the most common cause of inflammatory arthritis worldwide, with 1–2 in every 100 people estimated to be affected by gout. It is also frequently associated with co-morbidities such as diabetes mellitus, depression, cardiovascular disease, and chronic pulmonary diseases. It can be very painful and debilitating, but the effect on quality of life can be reduced with good management.

The BSR guideline is intended to offer revised and updated, concise, patient-focused, evidence-based, expert recommendations for the management of gout in the UK.

The following areas are covered in the May 2017 update of the guideline:

  • the availability of new pharmaceutical treatment options
  • recent increases in the incidence, prevalence, and severity of gout
  • the continuing suboptimal management in both primary and secondary care
  • better understanding of patient and provider barriers to effective care.

It should be noted that this guideline does not cover diagnosis or investigation of gout.